Trial Profile
A Multicenter, Single-arm, Phase II Exploratory Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line Anticancer Agent in NSCLC Patients With EGFR Mutation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Olmutinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Hanmi Pharmaceutical
- 23 Apr 2018 Status changed from active, no longer recruiting to completed.
- 02 Feb 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Dec 2016 as reported by Clinicaltrials.gov record.
- 02 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by Clinicaltrials.gov record.